Neuroendocrine Tumor Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Neuroendocrine Tumor (NET) Treatment Market will experience over 9% CAGR between 2024 and 2032, due to increased awareness regarding early diagnosis with advancements in medical imaging and diagnostic technologies. Furthermore, the increasing prevalence of neuroendocrine tumors (NETs) and the heightened demand for personalized treatment options are driving the swift development of targeted therapies and innovative drug formulations.

Continuous advancements in treatment modalities, such as peptide receptor radionuclide therapy (PRRT) and somatostatin analogs, are fueling market growth by offering patients more effective and tailored treatment solutions. In July 2024, Ipsen deepened its partnership with Exelixis to advance Cabometyx for treating advanced neuroendocrine tumors, buoyed by encouraging results from the CABINET Phase III trial. This collaboration is poised to drive market growth by offering advanced therapeutic options and demonstrates the trend for strategic deals across the sector.

The neuroendocrine tumor (NET) treatment market is segmented by therapy, indication, route of administration, end-use, and region.

During the forecast period, the targeted therapy segment is poised for significant growth, thanks to its precision and efficacy over traditional treatments. By homing in on specific molecular targets linked to NETs, targeted therapies not only boost treatment effectiveness but also safeguard healthy tissues. This precision not only betters patient outcomes but also curtails severe side effects, enhancing the overall quality of life. With deepening insights into the molecular and genetic traits of NETs, the push for targeted therapies becomes paramount, meeting the demand for personalized and potent treatment strategies.

The lung NET segment is set to capture a significant share of the neuroendocrine tumor (NET) treatment market by 2032, driven by the prominence and clinical emphasis on lung NETs. The lung NET indication is a key growth driver, attracting considerable R and D focus. This focus has spurred advancements in diagnostics and treatments specifically for lung NETs. Such attention translates to increased clinical trials and therapeutic innovations, broadening treatment avenues and propelling market growth. As lung NET incidences rise, so does the demand for specialized therapies, drawing heightened market investments.

Europe neuroendocrine tumor (NET) treatment market will record an upward trajectory through 2032, buoyed by increasing government support and funding for cancer research and treatment. The region boasts a strong healthcare infrastructure, adept at advanced diagnostics and treatments. An aging population further amplifies this demand. Moreover, a commitment to comprehensive cancer care programs and patient support services boosts treatment accessibility. Collaborative ventures among healthcare providers, research entities, and pharmaceutical firms in Europe are catalyzing swift innovations and market expansion.

Product Code: 10357

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of neuroendocrine tumors
  - 3.2.1.2 Development of new treatments
  - 3.2.1.3 Supportive government policies, grants, and funding for research in oncology
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of development
  - 3.2.2.2 Lack of awareness among the people
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Somatostatin analogs (SSAs)
5.3 Targeted therapy
5.4 Chemotherapy
5.5 Other therapies

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Lungs NET
6.3 Pancreatic NET
6.4 Gastrointestinal NET
6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals and clinics
8.3 Cancer treatment centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 AVEO Pharmaceuticals, Inc.
10.2 Boehringer Ingelheim International GmbH
10.3 Bristol-Myers Squibb
10.4 Eli Lilly and Company
10.5 F. Hoffmann-La Roche Ltd.
10.6 Hutchison MediPharma Limited
10.7 Ipsen
10.8 Jubilant Life Sciences Ltd.
10.9 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
10.10 Novartis AG
10.11 Pfizer Inc.
10.12 Tarveda Therapeutics